The improved sensitivity of AFP-L3 over AFP (46.6% vs. 34.5%) observed in a Latin American cohort of patients with cirrhosis suggests its potential for enhanced HCC detection in this population, though further validation is warranted (Beudeker et al. 2023) (Table 1). This evidence concerns the gene AFP and hepatocellular carcinoma.